FDG-PET response
| FDG-PET response, n = 20 evaluable . | CR (%) . | PR (%) . | ORR, % . |
|---|---|---|---|
| COO/subtype | |||
| GC, n = 3 | 1 (33) | 0 (0) | 33 |
| Non-GC, n = 8 | 8 (100)* | 0 (0) | 100 |
| PMBL, n = 4 | 0 (0) | 4 (100) | 100 |
| Richter, n = 5 | 2 (40) | 3 (60) | 100 |
| Overall, n = 20 | 11 (55) | 7 (35) | 90 |
| FDG-PET response, n = 20 evaluable . | CR (%) . | PR (%) . | ORR, % . |
|---|---|---|---|
| COO/subtype | |||
| GC, n = 3 | 1 (33) | 0 (0) | 33 |
| Non-GC, n = 8 | 8 (100)* | 0 (0) | 100 |
| PMBL, n = 4 | 0 (0) | 4 (100) | 100 |
| Richter, n = 5 | 2 (40) | 3 (60) | 100 |
| Overall, n = 20 | 11 (55) | 7 (35) | 90 |
In univariate analysis, non-GC patients had a significantly increased rate of metabolic CR compared with other phenotypes (P = .008).